ClinicalTrials.gg
CompletedNCT06669754CHAPTER-3Updated Nov 6, 2026

Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE

A Phase 3 interventional study of Deucrictibant and Placebo in Hereditary Angioedema (HAE), sponsored by Pharvaris Netherlands B.V.. Completed at 56 sites in 24 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Pharvaris Netherlands B.V. · Phase 3, Interventional, and Treatment

Updated Nov 6, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
85
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 51 studies in Angioedemas, Hereditary with a site in United Kingdom — 9 open to participants now, 16 under way, 11 of them phase 3. Angioedemas, Hereditary · United Kingdom.

Enrollment
23rd of 43
85 · median 90
Started
2024
with 2 others
Phase 3
21 of 51
6 open now
Registered
43rd of 51
by date
Lead sponsor
7 of 51
Pharvaris Netherlands B.V.

Among the 51 studies in Angioedemas, Hereditary with a site in United Kingdom, this one is the 23rd largest by enrollment of the 43 interventional ones that give a count, is one of 3 that started in 2024, is one of 21 in phase 3, and was the 43rd registered.

Angioedemas, Hereditary

171 studies on the registry are indexed under Angioedemas, Hereditary; 24 are open to participants now.

Browse Angioedemas, Hereditary studies →

Open to participants now

9 of the 51 studies in Angioedemas, Hereditary with a site in United Kingdom are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 13 Angioedemas, Hereditary studies recruiting now, 9 (69%) set no upper age limit and 4 (31%) stop at 75 or younger; 7 take children under 18; 1 takes healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies in Angioedemas, Hereditary with a site in United Kingdom, or all of them as a file.
02

Study summary

This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of once-daily orally administered deucrictibant extended-release tablet compared to placebo for prophylaxis to prevent angioedema attacks in participants aged ≥ 12 years with hereditary angioedema.

Read the detailed description

The study consists of a Screening Period during which eligibility is confirmed, a Treatment Period of 24 weeks, and a Follow-up Period of maximum 4 weeks or subjects may roll over into the open-label study PHA022121-C307 (CHAPTER-4). During the Treatment period participants will receive blinded study drug (deucrictibant or placebo randomized in a 2:1 ratio). Participants will undergo regular efficacy and safety assessments, complete an electronic diary daily, and also complete questionnaires at predefined timepoints during the study.

03

Conditions studied

  • Hereditary Angioedema (HAE)

Keywords

  • HAE
  • Oral Treatment
  • Bradykinin B2 Receptor Antagonists
  • PHVS719
  • PHA121
  • Deucrictibant
  • Prophylaxis
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provision of written /assent.
  2. Male or female, aged ≥12 years at the time of providing written informed consent/assent.
  3. Diagnosis of hereditary angioedema (HAE)
  4. History of at least 3 HAE attacks within the 3 consecutive months prior to Screening Visit
  5. Predefined number of attacks during the Screening Period
  6. Reliable access and ability to use standard of care on-demand treatments to effectively manage acute HAE attacks.
  7. Willing and able to adhere to all protocol requirements, including eDiary and ePRO data recording.
  8. Female participants of must agree to the protocol specified pregnancy testing and methods.

Exclusion criteria

Exclusion Criteria:

  1. Any diagnosis of angioedema other than HAE
  2. Participation in a clinical study with any other drug within the last 30 days or within 5 half-lives of the investigational drug at Screening (whichever is longer)
  3. Has received prior prophylactic treatment with deucrictibant
  4. Exposure to ACE inhibitors or any estrogen-containing medications with systemic absorption within 4 weeks of Screening
  5. Prior gene therapy for any indication at any time
  6. Use of prophylactic treatment for HAE within 2 weeks of Screening for C1INH, oral kallikrein inhibitors, or anti-fibrinolytics; within 4 weeks of Screening for attenuated androgens; within 5 half-lives of Screening for monoclonal antibodies, or within 7 days of Screening for short-term prophylaxis
  7. Any females who are pregnant, plan to become pregnant, or are currently breast-feeding
  8. Abnormal hepatic function
  9. Moderate or severe renal impairment
  10. Any comorbidity or systemic dysfunction that would interfere with the participant's safety or ability to participate in the study.
  11. History of alcohol or drug abuse within the previous year, or current evidence of substance dependence or abuse
  12. Use of medications that are moderate and strong inhibitors or strong inducers of within the last 30 days or within 5 half-lives (whichever is longer) of the time of randomization
  13. Known to deucrictibant or any of the of the study drug
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
85 participants (actual)

Study arms

  • Experimental
    Active

    Deucrictibant 40mg extended-release tablet by mouth once daily

    Drug: Deucrictibant

  • Experimental
    Placebo

    Placebo 1 tablet by mouth once daily

    Drug: Placebo

Interventions

  • Deucrictibant 40mg extended-release tablet for once daily oral use

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Time-normalized (per 4 weeks) number of Investigator-confirmed HAE attacks during the 24-week Treatment Period

    Time frame: 24 weeks

Secondary outcomes

  1. Time-normalized number of Investigator-confirmed HAE attacks treated with on-demand medication during the 24-week Treatment Period

    Time frame: 24 weeks

  2. Time-normalized number of Investigator-confirmed moderate or severe HAE attacks during the 24-week Treatment Period

    Time frame: 24 weeks

  3. Time-normalized number of Investigator-confirmed severe HAE attacks during the 24-week Treatment Period

    Time frame: 24 weeks

  4. Proportion of participants achieving ≥50% reduction in HAE attack rate relative to baseline during the 24-week Treatment Period

    Time frame: 24 weeks

  5. Proportion of participants achieving ≥70% reduction in HAE attack rate relative to baseline during the 24-week Treatment Period

    Time frame: 24 weeks

  6. Proportion of participants achieving ≥90% reduction in HAE attack rate relative to baseline during the 24-week Treatment Period

    Time frame: 24 weeks

  7. Proportion of participants that are HAE attack-free during the 24-week Treatment Period

    Time frame: 24 weeks

  8. Proportion of time without angioedema symptoms during the 24-week Treatment Period

    Time frame: 24 weeks

  9. Incidence of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), adverse events of special interest (AESIs), and TEAEs leading to study drug discontinuation

    Time frame: Up to 38 weeks

  10. Pharmacokinetics [PK]: Deucrictibant plasma concentration time profiles

    Time frame: 24 weeks

  11. Patient reported outcome: Angioedema Quality of Life (AE-QoL) questionnaire

    The AE-QoL is a short 17-item questionnaire designed to retrospectively assess HRQoL, with a recall period of 4 weeks. Its results can be displayed as a total score or as 4 domain scores. The scores range from 0 to 100, after linear transformation of raw values, with higher scores indicating higher HRQoL impairment.

    Time frame: 24 weeks

  12. Patient reported outcome: Patient Global Assessment of Change (PGA-Change)

    PGA-Change assesses on a 5-point scale how the participant's QoL has been impacted by HAE since start taking the study drug

    Time frame: 24 weeks

  13. Patient reported outcome: Angioedema Control Test 4-week version (AECT-4wk)

    AECT-4wk measures disease control retrospectively, it comprises 4 questions over a 4-week recall period. Scores for the responses in the AECT range from 0 to 16, with higher scores indicating better disease control (≤ 9 poorly controlled; ≥ 10 well controlled)

    Time frame: 24 weeks

  14. Patient reported outcome: Work Productivity and Activity Impairment Questionnaire - Specific Health Problem (WPAI-SHP)

    WPAI-SHP is a questionnaire assessing how a health condition impacts a person's ability to work and do regular activities and it includes 4 domains. Scores indicate the percentage of time the patient missed work or was less productive owing to HAE-related complications.

    Time frame: Up to 34 weeks

  15. Patient reported outcome: Abbreviated Treatment Satisfaction Questionnaire for Medication (TSQM-9)

    TSQM-9 is a 9-item questionnaire evaluating patient treatment satisfaction and it includes 3 domains. Scoring is by domain and each domain score is computed by summing the individual TSQM items in each domain and then transforming the composite score into a value ranging from 0 to 100, with higher scores indicating higher satisfaction.

    Time frame: Up to 34 weeks

07

Study locations

56 sites
  • Study Site
    Little Rock, Arkansas 72205, United States
  • Study Site
    San Diego, California 92122, United States
  • Study site
    Santa Monica, California 90404, United States
  • Study site
    Walnut Creek, California 94598, United States
  • Study Site
    Chevy Chase, Maryland 20915, United States
  • Study Site
    St Louis, Missouri 63141, United States
  • Study Site
    Corrientes, Argentina
  • Study Site
    San Martin, Argentina
  • Study Site
    Santo André, Brazil
  • Study Site
    Sofia, 1431, Bulgaria
  • Study Site
    Sofia, 1680, Bulgaria
  • Study Site
    Edmonton, Canada
  • Study Site
    Ottawa, Canada
  • Study Site
    Grenoble, France
  • Study Site
    Lille, 59037, France
  • Study Site
    Berlin, Germany
  • Study Site
    Frankfurt, Germany
  • Study Site
    Hanover, Germany
  • Study Site
    Hong Kong, Hong Kong
  • Study Site
    Budapest, Hungary
  • Study Site
    Dublin, Ireland
  • Study Site
    Milan, 20062, Italy
  • Study Site
    Padova, Italy
  • Study Site
    Kawasaki, Japan
  • Study Site
    Tokyo, 113-0033, Japan
  • Study Site
    Tokyo, 1130033, Japan
  • Study Site
    Auckland, New Zealand
  • Study Site
    Krakow, Poland
  • Study Site
    San Juan, Puerto Rico
  • Study Site
    Sângeorgiu de Mureş, Romania
  • Study Site
    Singapore, Singapore
  • Study Site
    Martin, Slovakia
  • Study Site
    Cape Town, South Africa
  • Study Site
    Daegu, South Korea
  • Study Site
    Seoul, 06351, South Korea
  • Study Site
    Seoul, South Korea
  • Study Site
    Suwon, South Korea
  • Study Site
    Barcelona, 08013, Spain
  • Study Site
    Barcelona, 08907, Spain
  • Study Site
    Seville, Spain
  • Study Site
    Basel, Switzerland
  • Study Site
    Ankara, Turkey (Türkiye)
  • Study Site
    Istanbul, Turkey (Türkiye)
  • Study Site
    Izmir, Turkey (Türkiye)
  • Study site
    London, England E1 1FR, United Kingdom
  • Study Site
    Birmingham, B18 7QH, United Kingdom
  • Study Site
    Birmingham, B9 5SS, United Kingdom
  • Study Site
    Bristol, BS10 5NB, United Kingdom
  • Study Site
    Cambridge, CB2 0QQ, United Kingdom
  • Study Site
    Frimley, GU16 7UJ, United Kingdom
  • Study Site
    Leeds, LS9 7TF, United Kingdom
  • Study Site
    London, NW3 2QG, United Kingdom
  • Study Site
    Oxford, United Kingdom
  • Study site
    Plymouth, PL6 5FP, United Kingdom
  • Study Site
    Southampton, United Kingdom
  • Study Site
    Stoke, United Kingdom
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2024 to primary completion in Jul 2026, 19 months.

Of 46 industry-sponsored phase 3 interventional studies under Angioedemas, Hereditary, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 33. This study's 19 months is below that.

Counting every sponsor, half of 46 studies reached it within 22 months; a quarter within 16 and three quarters within 33.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 6, 2026: primary completion Aug 2026 → Jul 2026 and completion Aug 2026 → Jul 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 24, 2024
First posted
Nov 1, 2024
StartActual
Dec 1, 2024
Primary completionActual
Jul 21, 2026was Aug 2026
CompletionActual
Jul 21, 2026was Aug 2026
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Nov 6, 2026
Primary completion
Aug 2026→Jul 21, 2026 (actual)
Nov 6, 2026
Study completion
Aug 2026→Jul 21, 2026 (actual)
Nov 6, 2026
Enrollment
81 (estimated)→85 (actual)
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Active, not recruiting→Completed
    Primary completion Aug 2026→Jul 21, 2026 (now actual)
    Study completion Aug 2026→Jul 21, 2026 (now actual)
    Enrollment 81 (estimated)→85 (actual)
    + 2 other changes: verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06669754
Lead sponsor
Pharvaris Netherlands B.V.
Responsible party
Sponsor
First posted
Nov 1, 2024
Start date
Dec 1, 2024
Primary completion
Jul 21, 2026
Completion
Jul 21, 2026
Last update
Nov 6, 2026

Study contacts

Study Director, Pharvaris
study director · Pharvaris Netherlands B.V.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Deucrictibant

Start the discussion